Stryker Corporation $SYK Shares Sold by Fulton Breakefield Broenniman LLC

Key Points

• Fulton Breakefield Broenniman LLC cut its Stryker stake by 13% in the second quarter, selling 6,390 shares and retaining 42,649 shares valued at approximately $13.4 million. Institutional investors and hedge funds own 77.09% of the company.
• Stryker reported quarterly earnings of $3.69 per share, exceeding estimates of $3.49, while revenue rose 9.4% year over year to $6.59 billion. The company issued full-year 2026 EPS guidance of $14.95 to $15.10.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $386.28 price target, despite several recent target reductions. Stryker also declared a quarterly dividend of $0.88 per share, representing a 1.0% yield.

Fulton Breakefield Broenniman LLC reduced its stake in shares of Stryker Corporation (NYSE:SYK - Free Report) by 13.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 42,649 shares of the medical technology company's stock after selling 6,390 shares during the period. Fulton Breakefield Broenniman LLC's holdings in Stryker were worth $13,428,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Elyxium Wealth LLC purchased a new stake in Stryker in the second quarter valued at approximately $206,000. Everett Harris & Co. CA raised its stake in Stryker by 1.3% during the second quarter. Everett Harris & Co. CA now owns 5,937 shares of the medical technology company's stock worth $1,869,000 after purchasing an additional 75 shares during the period. Bryn Mawr Trust Advisors LLC raised its stake in Stryker by 2.1% during the second quarter. Bryn Mawr Trust Advisors LLC now owns 3,529 shares of the medical technology company's stock worth $1,111,000 after purchasing an additional 73 shares during the period. Osprey Private Wealth LLC boosted its holdings in shares of Stryker by 32.4% in the 2nd quarter. Osprey Private Wealth LLC now owns 13,889 shares of the medical technology company's stock valued at $4,373,000 after purchasing an additional 3,398 shares during the last quarter. Finally, Oppenheimer & Co. Inc. boosted its holdings in shares of Stryker by 7.0% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 26,062 shares of the medical technology company's stock valued at $8,205,000 after purchasing an additional 1,700 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Price Performance

SYK opened at $338.80 on Friday. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $396.86. The company has a 50 day moving average of $324.61 and a two-hundred day moving average of $333.57. The company has a market cap of $129.95 billion, a P/E ratio of 35.11, a P/E/G ratio of 2.17 and a beta of 0.76. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating analysts' consensus estimates of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business's revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter last year, the firm posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, analysts expect that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker's dividend payout ratio (DPR) is 36.48%.

Insider Transactions at Stryker

In other news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the firm's stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the sale, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 4.60% of the company's stock.

Wall Street Analysts Forecast Growth

SYK has been the subject of several research reports. Royal Bank Of Canada lowered their price objective on shares of Stryker from $435.00 to $420.00 and set an "outperform" rating for the company in a research note on Friday, July 31st. Citizens Jmp reduced their target price on Stryker from $440.00 to $400.00 and set a "market outperform" rating on the stock in a report on Monday, August 3rd. Barclays reduced their target price on Stryker from $469.00 to $394.00 and set an "overweight" rating on the stock in a report on Monday, May 4th. Weiss Ratings restated a "hold (c)" rating on shares of Stryker in a research note on Friday, July 31st. Finally, JPMorgan Chase & Co. cut their price objective on Stryker from $400.00 to $350.00 and set an "overweight" rating on the stock in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Stryker has an average rating of "Moderate Buy" and a consensus price target of $386.28.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source